Tivumecirnon, also known as FLX475, is a CCR4 antagonist with potential as an antineoplastic agent. Tivumecirnon promotes anti-tumor activity by blocking the migration of regulatory T-cells into tumors (specifically EBV-positive tumors). The secretion of Chemokines by tumors triggers the migration of the immunosuppressing regulatory T-cells to the site of the tumor. By inhibiting the migration of the regulatory T-cells, the natural anti-tumor activity of the immune system is restored. Phase 1 trials for Tivumecirnon have been completed, with Phase 2 of the Phase 1/2 portion of the trial underway.
MedKoo Cat#: 207053
Name: Tivumecirnon HCl
CAS#: Tivumecirnon HCl
Chemical Formula: C24H29Cl4F3N6O
Exact Mass: 0.0000
Molecular Weight: 616.33
Elemental Analysis: C, 46.77; H, 4.74; Cl, 23.01; F, 9.25; N, 13.64; O, 2.60
The following data is based on the product molecular weight 616.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
